 |
Eligard
|
| How it Works |
Eligard® is administered using the Atrigel® drug delivery platform, which allows for the extended or time-released delivery of drug therapies.
Eligard is prefilled and supplied in two separate, sterile syringes. One syringe contains the Atrigel delivery system and the other contains leuprolide acetate. The contents are mixed immediately prior to administration. The two syringes are joined and the single dose product is mixed until it is homogenous. Eligard is administered subcutaneously where it forms a solid drug delivery depot. In this form, the drug is released slowly for weeks or even months to come. When the drug is completely released, the remaining material is absorbed by the body with no significant side effects.
For the Eligard formulation, the Atrigel delivery system is a polymeric (non-gelatin containing) delivery system consisting of a biodegradable poly (DL-lactide-co-glycolide) (PLGH) polymer formulation dissolved in a biocompatible solvent, N-methyl-2-pyrrolidone (NMP). PLGH is a co-polymer with a 50:50 molar ratio of DL-lactide to glycolide containing carboxyl end groups. The second syringe contains leuprolide acetate and the constituted product is designed to deliver the specified amount of leuprolide acetate at the time of subcutaneous injection. |
|
| |
|
|
|
|
|
|
|
|
